« Return to News | CROs/Service Providers

Datatrak Revenue Down 37% in Q2

Tuesday, August 21, 2007 07:29 AM

Datatrak, an electronic data capture company, reported its second quarter revenue slumped 37% to $3.07 million and a net loss of $2.97 million or $0.22 per share on a basic and diluted basis. These results compared with revenue of $4.83 million and a net loss of $702,000, or $0.06 per share basic and diluted basis, in the second quarter of 2006. Datatrak laid off 17 employees in the second quarter, recording severance charges totaling $337,000.

The employee reductions in June are expected to decrease annual direct costs by approximately $515,000 and annual expenses by approximately $875,000, for a total cost reduction of approximately $1.4 million per year.

“During the second quarter, we instituted monumental changes at Datatrak,” stated Jeffrey Green, president and chief executive officer of Datatrak. “These changes have not only been related to cost cutting, but also relate to the current reorganization of our entire sales and marketing strategy that clearly was not producing the growth we believe possible with our product offerings. Though it may sound like a contradiction to some, while cost cutting in some areas, we are investing heavily in sales and marketing.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.